SCHEMBL3479700

SCHEMBL3479700

CN1CCN(c2ccc(Cl)cc2)c2ccc(-c3ncccn3)cc2C1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 1/20 0.46
HRH4 Q9H3N8 5/20 0.40
HTR6 P50406 1/20 0.40
HRH3 Q9Y5N1 1/20 0.40
LMNA P02545 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MAPKAPK2 P49137 2/20 0.39
BRD4 O60885 6/20 0.39
BRD2 P25440 5/20 0.39
AVPR2 P30518 1/20 0.38
AVPR1A P37288 1/20 0.38
KCNH2 Q12809 1/20 0.38
POLB P06746 1/20 0.37
BRD3 Q15059 4/20 0.36
RET P07949 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3230914 0.89 SCN9A (0.45) SCN9AHRH4MAPKAPK2
SCHEMBL3479616 0.88 SCN9A (0.44) SCN9AHRH4LMNASMN1; SMN2MAPKAPK2
SCHEMBL3479963 0.88 HRH4 (0.44) SCN9AHRH4KCNH2
SCHEMBL3232247 0.88 SCN9A (0.48) SCN9AHRH4LMNASMN1; SMN2MAPKAPK2
SCHEMBL3240469 0.87 SCN9A (0.50) SCN9AHRH4HTR6HRH3LMNA
SCHEMBL3479576 0.86 SCN9A (0.44) SCN9AKCNH2KMT2A
SCHEMBL3240462 0.84 SCN9A (0.46) SCN9AHRH4HTR6HRH3MAPKAPK2
SCHEMBL3479598 0.84 HTR3A (0.46) SCN9AHRH4HTR6HRH3SMN1; SMN2
SCHEMBL3480219 0.83 HRH4 (0.43) SCN9AHRH4HTR6HRH3LMNA
SCHEMBL3479538 0.83 SCN9A (0.43) SCN9AHRH4MAPKAPK2KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096546-B2 Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin ALBANY MOLECULAR RESEARCH, INC. (US) 2015-08-04 US claimed
US-9096546-B2 Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin ALBANY MOLECULAR RESEARCH, INC. (US) 2015-08-04 US disclosed
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ALBANY MOLECULAR RESEARCH, INC. (US) 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ADRA1B, ADRB1, ADRA1D SCN9A 795/4885HRH4 90/4885HTR6 73/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.